Management Options for Thrombophilias

ABSTRACT

Thrombophilias may be inherited or acquired, continuing or transient, and may contribute strongly or weakly to thrombosis. They may predispose to venous thromboembolism alone or also to artery occlusion. Advice on management must recognize these variations. The presence of an inherited thrombophilia should not alter the intensity of anticoagulant therapy, given that antithrombin, protein C, or protein S deficiency, factor V Leiden, and the prothrombin G20210A mutation are not unusually anticoagulant resistant. However, they can increase the optimal treatment duration after a first thromboembolic event. Optimal duration depends on the balance between thrombosis risk off treatment and bleeding risk during extended anticoagulant therapy, and needs to be separately estimated for each individual with thrombosis and thrombophilia. The higher the thrombosis risk and the lower the bleeding risk, the longer the optimal treatment duration. This balance favors continued (but perhaps not indefinite) therapy in antithrombin, protein C, and protein S deficiency, and perhaps also in patients with the factor V Leiden or prothrombin mutations if their bleeding risk is low. Thrombosis that complicates active malignancy, the antiphospholipid syndrome, or heparin-induced thrombocytopenia needs special consideration: recent clinical trials suggest that low molecular weight heparins are more effective than warfarin in thrombosis with cancer, and that a more intense warfarin effect is not needed for patients with antiphospholipid syndrome and thrombosis. Debate continues about the place of screening for presymptomatic but affected relatives of patients with thrombosis and an inherited predisposition. It is essential that any family testing be done only with the informed consent of all concerned. Given consent, there is general support for family testing in antithrombin, protein C, or protein S deficiency and where the factor V Leiden or prothrombin mutation is strongly penetrant and expressed. There is, however, a strong argument that any testing in families in which clotting factor polymorphisms are weakly expressed should be restricted to young women when they consider hormonal contraception or pregnancy, given that these acquired factors multiply the risk.

KEYWORDS

Thrombosis - thrombophilia - treatment intensity - treatment duration - family testing

REFERENCES

• 1 Press R D, Bauer K A, Kujovich J L, Heit J A. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders.  Arch Pathol Lab Med. 2002;  126 1304-1318
• 2 Rosendaal F R. Venous thrombosis: a multicausal disease.  Lancet. 1999;  353 1167-1173
• 3 van Cott E M, Laposata M, Prins M H. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis: venous thromboembolism, myocardial infarction, stroke, and other conditions.  Arch Pathol Lab Med. 2002;  126 1281-1295
• 4 Prandoni P, Lensing A W A, Cogo A et al.. The long-term course of acute deep venous thrombosis.  Ann Intern Med. 1996;  125 1-7
• 5 Heit J A, Mohr D N, Silverstein M D, Petterson T M, O'Falloon W M, Melton L J. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.  Arch Intern Med. 2000;  160 761-768
• 6 Büller H R, Prins M H. Secondary prophylaxis with warfarin for venous thromboembolism.  N Engl J Med. 2003;  349 702-704
• 7 Schulman S, Rhedin A-S, Lindmarker P et al.. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism.  N Engl J Med<. 1995;  332 1661-1665
• 8 Pinede L, Ninet J, Duhaut P et al.. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis.  Circulation. 2001;  103 2453-2460
• 9 Prandoni P, Lensing A W A, Prins M H et al.. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism.  Ann Intern Med. 2002;  137 955-960
• 10 Prandoni P, Lensing A W A, Piccioli A et al.. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.  Blood. 2002;  100 3484-3488
• 11 Hansson P-O, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors.  Arch Intern Med. 2000;  160 769-774
• 12 Douketis J D, Foster G A, Crowther M A, Prins M H, Ginsberg J S. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.  Arch Intern Med. 2000;  160 3431-3436
• 13 Murin S, Romano P S, White R H. Comparisons of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism.  Thromb Haemost. 2002;  88 407-414
• 14 Levine M N, Hirsh J, Gent M et al.. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal DVT.  Thromb Haemost. 1995;  74 606-611
• 15 Agnelli G, Prandoni P, Beccatini C et al.. Extended oral anticoagulant therapy after a first episode of pulmonary embolism.  Ann Intern Med. 2003;  139 19-25
• 16 Kearon C, Gent M, Hirsh J et al.. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.  N Engl J Med. 1999;  340 901-907
• 17 Agnelli G, Prandoni P, Sanatamaria M G et al.. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis.  N Engl J Med. 2001;  345 165-169
• 18 Schulman S, Granqvist S, Holmström M et al.. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism.  N Engl J Med. 1997;  336 393-398
• 19 Schulman S. Care of patients receiving long-term anticoagulant therapy.  N Engl J Med. 2003;  349 675-683
• 20 Vink R, Kraaijenhagen R A, Levi M, Büller H R. Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on decision model.  J Thromb Haemost. 2003;  1 2523-2530
• 21 Ridker P M, Goldhaber S Z, Danielson E et al.. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.  N Engl J Med. 2003;  348 1425-1434
• 22 Kearon C, Ginsberg J, Kovacs M et al.. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.  N Engl J Med. 2003;  349 631-639
• 23 Lemmer Jr J H, Despotis G J. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery.  J Thorac Cardiovasc Surg. 2002;  123 213-217
• 24 Chan Y C, Valenti D, Mansfield A O, Stansby G. Warfarin induced skin necrosis.  Br J Surg. 2000;  87 266-272
• 25 Emmerich J, Rosendaal F R, Cattaneo M et al.. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3204 controls.  Thromb Haemost. 2001;  86 809-816
• 26 Hirsh J, Kearon C, Ginsberg J. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia.  Arch Intern Med. 1997;  157 2174-2177
• 27 Middeldorp S, Büller H R. How to decide on the optimal duration of anticoagulant therapy in carriers of the factor V Leiden mutation.  Thromb Haemost. 2000;  84 740-741
• 28 Sarasin F P, Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episodes of deep vein thrombosis.  BMJ. 1998;  316 95-99
• 29 Bauer K A. Management of thrombophilia.  J Thromb Haemost. 2003;  1 1429-1434
• 30 van den Belt A G, Hutten B A, Prins M H, Bossuyt P M M. Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S-a decision analysis.  Thromb Haemost. 2000;  84 758-763
• 31 Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.  Lancet. 2003;  362 523-526
• 32 Machin S J. Pros and cons of thrombophilia testing: cons.  J Thromb Haemost. 2003;  1 412-413
• 33 Martinelli I. Rebuttal to: pros and cons of thrombophilia testing-cons.  J Thromb Haemost. 2003;  1 1311-1312
• 34 Palareti G, Legnani C, Cosmi B et al.. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation in subjects with a previous idiopathic event and in cases of congenital thrombophilia.  Circulation. 2003;  108 313-318
• 35 Langlois N J, Wells P S. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review.  Thromb Haemost. 2003;  90 17-26
• 36 Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci P M. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both.  Br J Haematol. 2000;  111 1223-1229
• 37 Nguyen A. Prothrombin G20210A polymorphism and thrombophilia.  Mayo Clin Proc. 2000;  75 595-604
• 38 Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci P M. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis.  Arterioscler Thromb Vasc Biol. 1999;  19 700-703
• 39 Martinelli I, Bucciarelli P, Zighetti M L, Cafro A, Mannucci P M. Low risk of thrombosis in family members of patients with hyperhomocysteinemia.  Br J Haematol. 2002;  117 709-711
• 40 Ryan D H, Crowther M A, Ginsberg J S, Francis C W. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery.  Ann Intern Med. 1998;  128 270-276
• 41 Wahlander K, Larson G, Lindahl T L et al.. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.  Thromb Haemost. 2002;  87 580-585
• 42 Mannucci P M. Genetic hypercoagulability: prevention suggests testing family members.  Blood. 2001;  98 21-22
• 43 Martinelli I. Pros and cons of thrombophilia testing: pros.  J Thromb Haemost. 2003;  1 410-411
• 44 Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci P M. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium.  Thromb Haemost. 2002;  87 791-795
• 45 Scarabin P-Y, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.  Lancet. 2003;  362 428-432
• 46 Olson J D, Arkin C F, Brandt J T et al.. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy.  Arch Pathol Lab Med<. 1998;  122 782-798
• 47 Green D. Genetic hypercoagulability: screening should be an informed choice.  Blood. 2001;  98 20
• 48 Vandenbroucke J P, van der Meer F J M, Helmerhorst F M, Rosendaal F R. Factor V Leiden: should we screen oral contraceptive users and pregnant women?.  BMJ. 1996;  313 1127-1130
• 49 Brenner B R, Nowak-Göttl U, Kosch A, Manco-Johnson M, Laposata M. Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and in children.  Arch Pathol Lab Med. 2002;  126 1296-1303
• 50 Lee A Y, Levine M N, Baker R I et al.. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.  N Engl J Med<. 2003;  349 146-153
• 51 Levine J S, Branch D W. The antiphospholipid syndrome.  N Engl J Med. 2002;  346 752-763
• 52 Derksen RHW M, de Groot P G, Kater L, Nieuwenhuis H K. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment.  Ann Rheum Dis. 1993;  52 689-692
• 53 Triplett D A. Antiphospholipid antibodies.  Arch Pathol Lab Med. 2002;  126 1424-1429
• 54 Khamashta M A, Cuadrano M J, Mujic F, Taub N A, Hunt B J, Hughes G R V. The management of thrombosis in the antiphospholipid antibody syndrome.  N Engl J Med. 1995;  332 993-997
• 55 Rosove M H, Brewer P M C. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.  Ann Intern Med. 1992;  117 303-308
• 56 Crowther M A, Ginsberg J S, Julian J et al.. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.  N Engl J Med<. 2003;  349 1133-1138
• 57 Tripodi A, Chantarangkul V, Clerici M, Negri B, Galli M, Mannucci P M. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins.  Br J Haematol<. 2001;  115 672-678
• 58 Greaves M. Antiphospholipid antibodies and thrombosis.  Lancet. 1999;  353 1348-1353
• 59 Runchey S S, Folsom A R, Tsai M Y, Cushman M, McGovern P D. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study.  Br J Haematol. 2002;  119 1005-1010
• 60 Pasquier E, Amiral J, de Saint Martin L, Mottier D. A cross-sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism.  Thromb Haemost. 2001;  86 538-542
• 61 Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy.  Am J Med. 1998;  104 332-338
• 62 Warkentin T E. Heparin-induced thrombocytopenia: pathogenesis and management.  Br J Haematol. 2003;  121 535-555
• 63 Chong B H. Heparin-induced thrombocytopenia.  J Thromb Haemost. 2003;  1 1471-1478
• 64 Alving B M. How I treat heparin-induced thrombocytopenia and thrombosis.  Blood. 2003;  101 31-37
• 65 Fohlen-Walter A, de Maistre E, Marchand-Arvier M, Lecompte T. Does negative heparin-platelet factor 4 enzyme-linked immunosorbent assay effectively exclude heparin-induced thrombocytopenia?.  J Thromb Haemost. 2003;  1 1844-1845
• 66 Chong B H, Gallus A S, Cade J F et al.. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosi.  Thromb Haemost. 2001;  86 1170-1175
• 67 Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.  Thromb Haemost. 2001;  85 950-957
• 68 Kodityal S, Manhas A H, Udden M, Rice L. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failure.  Eur J Haematol. 2003;  71 109-113
• 69 Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.  Circulation. 2003;  108 2062-2065
• 70 Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH).  Blood. 2003;  102 3587-3591
• 71 Schulman S, Wahlander K, Lundstrom T, Billing Classon S, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.  N Engl J Med. 2003;  349 1713-1721
• 72 Verheugt F W A. Can we pull the plug on warfarin in atrial fibrillation?.  Lancet. 2003;  362 1686-1687